<DOC>
<DOCNO>EP-0643045</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Quinoline derivatives as leukotriene antagonists
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D21500	C07D22100	C07D22116	C07D21514	C07D21518	C07D21520	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	C07D	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D215	C07D221	C07D221	C07D215	C07D215	C07D215	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of the formula I 
<
IMAGE
>
 wherein R1-R5, X, Ar and Y have the meaning indicated in the description, have useful pharmaceutical properties and are particularly active as leukotriene antagonists. They are prepared in a manner known per se.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
NOVARTIS AG
</APPLICANT-NAME>
<APPLICANT-NAME>
NOVARTIS ERFIND VERWALT GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
NOVARTIS AG
</APPLICANT-NAME>
<APPLICANT-NAME>
NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H.
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BECK ANDREAS DR
</INVENTOR-NAME>
<INVENTOR-NAME>
GERSPACHER MARC DR
</INVENTOR-NAME>
<INVENTOR-NAME>
VON SPRECHER ANDREAS DR
</INVENTOR-NAME>
<INVENTOR-NAME>
BECK, ANDREAS, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
GERSPACHER, MARC, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
VON SPRECHER, ANDREAS, DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
A compound of formula I,


wherein

R
1
 and R
2
 are each independently of the other hydrogen, lower alkyl, halo-lower alkyl,
halogen, lower alkoxy or halo-lower alkoxy, or
R
1
 and R
2
 together form -(CH
2
)
m
-, wherein m is 3, 4 or 5,
R
3
 is hydrogen, lower alkyl, or (carboxy- or lower alkoxycarbonyl-)phenyl-lower alkyl,
which may be additionally substituted on the phenyl ring by lower alkoxy,
R
4
 and R
5
 are each independently of the other lower alkyl, or
R
4
 and R
5
 together form -(CH
2
)
n
-, wherein n is 3, 4, 5 or 6,
X is O or S,
Ar is 1,3-phenylene or 2,7-naphthylene, and
Y is hydroxy or lower alkoxy;

the term "lower" denoting a radical having up to and including 7 carbon atoms;

or a salt thereof.
A compound of formula I according to claim 1, wherein the term "lower" denotes a
radical having up to and including 4 carbon atoms.
A compound of formula I according to claim 1, wherein R
1
 and R
2
 are each 
independently of the other hydrogen, lower alkyl, halo-lower alkyl, halogen, lower alkoxy

or halo-lower alkoxy, or R
1
 and R
2
 together form -(CH
2
)
3
- or -(CH
2
)
4
-, R
3
 is hydrogen,
lower alkyl, or (carboxy- or C
1
-C
7
alkoxycarbonyl-)phenyl-lower alkyl, which may be
additionally substituted on the phenyl ring by lower alkoxy, R
4
 and R
5
 are each
independently of the other lower alkyl, or R
4
 and R
5
 together form -(CH
2
)
4
- or -(CH
2
)
5
-,
X is O or S, Ar is 1,3-phenylene or 2,7-naphthylene, and Y is hydroxy or lower alkoxy;

or a salt thereof.
A compound of formula I according to claim 1, wherein R
1
 and R
2
 are each
independently of the other hydrogen, lower alkyl, trifluoromethyl, halogen or lower

alkoxy, R
3
 is hydrogen, lower alkyl or (carboxy- or C
1
-C
7
alkoxycarbonyl-)pheny]-lower

alkyl, R
4
 and R
5
 are each independently of the other lower alkyl, or R
4
 and R
5
 together
form -(CH
2
)
4
- or -(CH
2
)
5
-, X is O or S, Ar is 1,3-phenylene or 2,7-naphthylene, and Y is
hydroxy or lower alkoxy; or a salt thereof.
A compound of formula I according to claim 1, wherein R
1
 and R
2
 are each
independently of the other hydrogen, lower alkyl, trifluoromethyl, halogen or lower

alkoxy, R
3
 is hydrogen, lower alkyl or carboxyphenyl-lower alkyl, R
4
 and R
5
 are each
independently of the other lower alkyl, or R
4
 and R
5
 together form -(CH
2
)
4
- or -(CH
2
)
5
-,
X is O or S, Ar is 1,3-phenylene or 2,7-naphthylene, and Y is hydroxy or lower alkoxy, or

a pharmaceutically acceptable salt thereof.
A compound of formula I according to claim 1, wherein R
1
 is hydrogen, lower alkyl,
trifluoromethyl, halogen or lower alkoxy, R
2
 and R
3
 are hydrogen, R
4
 and R
5
 are each
independently of the other C
1
-C
3
alkyl, or R
4
 and R
5
 together form -(CH
2
)
4
- or -(CH
2
)
5
-,
X is O or S, Ar is 1,3-phenylene or 2,7-naphthylene, and Y is hydroxy, or a

pharmaceutically acceptable salt thereof.
A compound according to claim 1 of formula la


wherein R
1
 and R
2
 are each independently of the other hydrogen, chlorine or fluorine, 
R
3
 is hydrogen, R
4
 and R
5
 are ethyl, X is O, and Y is hydroxy or lower alkoxy, or a
pharmaceutically acceptable salt thereof.
A compound according to claim 6 of formula Ia, wherein R
1
 is hydrogen, chlorine or
fluorine, R
2
 is hydrogen or fluorine, R
3
 is hydrogen, R
4
 and R
5
 are ethyl, X is O, and Y is
hydroxy, or a pharmaceutically acceptable salt thereof.
4-[3-(2-Quinolinylmethoxy)phenylamino]-2,2-diethyl-4-oxobutanoic acid according to

claim 1, or a pharmaceutically acceptable salt thereof.
4-[3-(7-Fluoro-2-quinolinylmethoxy)phenylamino]-2,2-diethyl-4-oxobutanoic acid

according to claim 1, or a pharmaceutically acceptable salt thereof.
4-[3-(7-Trifluoromethyl-2-quinolinylmethoxy)phenylamino]-2,2-diethyl-4-oxobutanoic

acid according to claim 1, or a pharmaceutically acceptable salt thereof.
</CLAIMS>
</TEXT>
</DOC>
